Press release - February 21st, 2013
Cerbomed opens up new markets: From March on t-VNS with NEMOS will be available in Italy for the treatment of epilepsies.
ERLANGEN, Germany, February 21st, 2013 – More than 500,000 patients suffer from epilepsy in Italy. Not all of them can be treated sufficiently with available anticonvulsive medication. Therefore the medical device company cerbomed GmbH from Erlangen, Germany, announces that, from March 2013 on, transcutaneous vagus nerve stimulation (t-VNS) with NEMOS will be available to Italian epilepsy patients. To address the Italian market, cerbomed is cooperating with MARVAMED, a medical devices sales specialist experienced in the Italian neurology market. This is the first, successful step in extending into new European markets. Cooperations with further European distributors should follow in the course of the year.
MARVAMED's managing director, Dr. Pierluigi Bertolotto, has more than 20 years’ experience in neuromodulation and neurosurgery. He has both technical know-how and a network with experts in the field of epilepsy. His company, MARVAMED, based in Genoa, is a distributor specializing in medical products for neuromodulation and functional neurosurgery. "Hard-to-treat epilepsy patients suffer severely, and currently there are only a few therapy alternatives. I am glad to announce that with the transcutaneous vagus nerve stimulator NEMOS, a promising therapy option is now available in Italy, too", Bertolotto declares.
"We are happy to cooperate with MARVAMED. Such an effective and experienced sales partner will let us offer t-VNS with NEMOS to patients in Italy", says Dr. Andreas Hartlep, Chief Executive Officer of cerbomed GmbH.
About t-VNS with NEMOS
Transcutaneous Vagus Nerve Stimulation is addressed to patients suffering from various difficult-to-treat neurological and psychiatric diseases. The t-VNS therapy uses the fact that a branch of the vagus nerve is located directly under the skin in areas of the outer ear and therefore can be stimulated through the skin (transcutaneously) with electrical impulses.
With NEMOS cerbomed developed and patented a special stimulator and a dedicated ear electrode for treatment of epilepsies with t-VNS. The stimulator, which is connected with the ear electrode, sends out the electrical impulses. With the transcutaneous vagus nerve stimulator NEMOS a targeted stimulation of the vagus nerve gets possible without the need of a surgery.
Cerbomed GmbH is an innovative medical device company located in Erlangen, Germany, that focuses on neuromodulation. The company, founded in 2005, focuses on transcutaneous Vagus Nerve Stimulation (t-VNS), which may offer an attractive therapy option for patients with hard-to-treat neurological and psychiatric illnesses.
In 2010 cerbomed received the European clearance (CE mark) for the transcutaneous Vagus Nerve Stimulation for the treatment of epilepsies and depression, in 2012 for the treatment of pain.
Currently two clinical studies are carried out regarding the effectiveness of t-VNS in patients with drug-resistant epilepsy and chronic migraine.
In September 2012 cerbomed entered into a strategic partnership with Cyberonics, Inc., the global market leader in vagus nerve stimulation.
NEMOS is already available for treating epilepsies in Germany and Austria, and in Italy from March 2013. Forthcoming cooperations with other distributors should make NEMOS available to epilepsy patients in Great Britain, France and Spain.
MARVAMED, based in Genoa, is a distributor specializing in medical products for neuromodulation and functional neurosurgery. The company was founded in March 2010 by Dr. Pierluigi Bertolotto, who has 20 years of experience in the neurology market, in the area of movement disturbances and pain.